Published on June 16, 2012 at 1:03 AM
Sunovion Pharmaceuticals Canada
Inc. today announced that the New Drug Submission (NDS) for LATUDA™
(lurasidone HCl), for the treatment of adult patients with acute
schizophrenia has been approved by Health Canada. "We are pleased that
LATUDA has achieved this significant milestone," said Douglas Reynolds,
President, Sunovion Pharmaceuticals Canada Inc. "More importantly,
LATUDA will provide patients in Canada suffering from schizophrenia a
new option that can help support their treatment goals for this serious
and complex disorder."
"Schizophrenia is a disease that is complex and a challenge to treat
effectively," said Dr. Philip Tibbo, Psychiatrist at Capital District
Health Authority and Director of the Nova Scotia Early Psychosis
Program in Halifax. "Each person suffering from schizophrenia is
different, and new treatment options are always needed. Effective,
individualized treatment that offers a balance between efficacy, safety
and tolerability can help support each patient to reach their treatment
goals."
"It is important to always have a number of treatment options available
for those living with schizophrenia." said Chris Summerville, Chief
Executive Officer of the Schizophrenia Society of Canada.
"Schizophrenia is treatable, and individual patient recovery is
possible. More choice in finding the right medication is vital, and
having more treatment options accessible to patients by all private and
public drug plans in Canada can help greatly in supporting their
recovery process."
SOURCE Sunovion Pharmaceuticals Canada Inc.